Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

386

Participants

Timeline

Start Date

October 12, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Bexagliflozin

tablets containing 20 mg bexagliflozin

DRUG

Sitagliptin

tablets containing 100 mg sitagliptin

DRUG

Placebo for sitagliptin

inactive tablets to match the appearance of sitagliptin tablets

DRUG

Placebo for bexagliflozin

inactive tablets to match the appearance of bexagliflozin tablets

Trial Locations (56)

28007

Clinical Research Site 9012, Madrid

32127

Clinical Research Site 1031, Port Orange

41009

Clinical Research Site 9011, Seville

41013

Clinical Research Site 9014, Seville

44262

Clinical Research Site 1008, Munroe Falls

46010

Clinical Research Site 9018, Valencia

46600

Clinical Research Site 9005, Alzira

60611

Clinical Research Site 1271, Chicago

66606

Clinical Research Site 1359, Topeka

78258

Clinical Research Site 1360, San Antonio

90806

Clinical Research Site 1358, Long Beach

91773

Clinical Research Site 1361, San Dimas

95648

Clinical Research Site 1357, Lincoln

08009

Clinical Research Site 1009, Berlin

08611

Clinical Research Site 1037, Trenton

695 00

Clinical Research Site 3119, Hodonín

293 01

Clinical Research Site 3123, Mladá Boleslav

779 00

Clinical Research Site 3120, Olomouc

181 00

Clinical Research Site 3112, Prague

796 01

Clinical Research Site 3122, Prostějov

Unknown

Clinical Research Site 9102, Balatonfüred

Clinical Research Site 9101, Balatongyörök

Clinical Research Site 9106, Budapest

Clinical Research Site 9107, Szeged

Clinical Research Site 9105, Zalaegerszeg

Clinical Research Site 9103, Zamárdi

Clinical Research Site 9015, Seville

260-0804

Clinical Research Site 6031, Chiba

272-8516

Clinical Research Site 6037, Chiba

277-0825

Clinical Research Site 6042, Chiba

819-0006

Clinical Research Site 6040, Fukuoka

819-0168

Clinical Research Site 6035, Fukuoka

300-0835

Clinical Research Site 6034, Ibaraki

300-1207

Clinical Research Site 6039, Ibaraki

306-0232

Clinical Research Site 6041, Ibaraki

310-0826

Clinical Research Site 6032, Ibaraki

582-0005

Clinical Research Site 6033, Ōsaka

424-0855

Clinical Research Site 6036, Shizuoka

323-0022

Clinical Research Site 6038, Tochigi

80-858

Clinical Research Site 7137, Gdansk

30-015

Clinical Research Site 7144, Krakow

31-209

Clinical Research Site 7142, Krakow

31-261

Clinical Research Site 7139, Krakow

31-530

Clinical Research Site 7141, Krakow

20-362

Clinical Research Site 7120, Lublin

20-538

Clinical Research Site 7138, Lublin

10-117

Clinical Research Site 7131, Olsztyn

60-819

Clinical Research Site 7143, Poznan

60-821

Clinical Research Site 7140, Poznan

61-655

Clinical Research Site 7136, Poznan

24-100

Clinical Research Site 7107, Puławy

87-100

Clinical Research Site 7128, Torun

03004

Clinical Research Site 9002, Alicante

04001

Clinical Research Site 9016, Almería

08023

Clinical Research Site 9017, Barcelona

08500

Clinical Research Site 9013, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theracos

INDUSTRY

NCT03115112 - Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects | Biotech Hunter | Biotech Hunter